

# Christophe Ginestier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5973720/publications.pdf>

Version: 2024-02-01

109  
papers

16,202  
citations

43973

48  
h-index

42291

92  
g-index

121  
all docs

121  
docs citations

121  
times ranked

18695  
citing authors

#	ARTICLE	IF	CITATIONS
1	ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. <i>Cell Stem Cell</i> , 2007, 1, 555-567.	5.2	3,550
2	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. <i>Cancer Research</i> , 2009, 69, 1302-1313.	0.4	1,067
3	Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. <i>Cancer Research</i> , 2009, 69, 3382-3389.	0.4	938
4	Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. <i>Stem Cell Reports</i> , 2014, 2, 78-91.	2.3	854
5	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. <i>Journal of Clinical Investigation</i> , 2010, 120, 485-497.	3.9	658
6	Aldehyde Dehydrogenase 1 <sup>+</sup> Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 45-55.	3.2	646
7	Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks. <i>Cancer Research</i> , 2011, 71, 614-624.	0.4	573
8	Gene expression profiling of breast cell lines identifies potential new basal markers. <i>Oncogene</i> , 2006, 25, 2273-2284.	2.6	494
9	Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/ $\beta$ -Catenin Signaling. <i>PLoS Biology</i> , 2009, 7, e1000121.	2.6	484
10	Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival. <i>Cancer Research</i> , 2011, 71, 3991-4001.	0.4	458
11	Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 777-785.	1.1	432
12	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. <i>Nature Chemistry</i> , 2017, 9, 1025-1033.	6.6	423
13	BRCA1 regulates human mammary stem/progenitor cell fate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1680-1685.	3.3	417
14	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. <i>Oncogene</i> , 2004, 23, 1377-1391.	2.6	293
15	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. <i>Molecular Cancer Research</i> , 2005, 3, 655-667.	1.5	201
16	Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity. <i>Cancer Research</i> , 2012, 72, 1853-1864.	0.4	200
17	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. <i>Journal of Pathology</i> , 2005, 207, 260-268.	2.1	198
18	Retinoid signaling regulates breast cancer stem cell differentiation. <i>Cell Cycle</i> , 2009, 8, 3297-3302.	1.3	193

#	ARTICLE	IF	CITATIONS
19	A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1/Neuregulin 1/Heregulin Gene. <i>Cancer Research</i> , 2004, 64, 6840-6844.	0.4	185
20	Immunophenotypic analysis of inflammatory breast cancers: identification of an inflammatory signature™. <i>Journal of Pathology</i> , 2004, 202, 265-273.	2.1	180
21	Junctional recruitment of mammalian Scribble relies on E-cadherin engagement. <i>Oncogene</i> , 2005, 24, 4330-4339.	2.6	180
22	Cancer Stem Cells in Breast: Current Opinion and Future Challenges. <i>Pathobiology</i> , 2008, 75, 75-84.	1.9	169
23	MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells. <i>PLoS Genetics</i> , 2012, 8, e1002751.	1.5	150
24	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. <i>Cancer Research</i> , 2005, 65, 767-79.	0.4	148
25	Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. <i>American Journal of Pathology</i> , 2002, 161, 1223-1233.	1.9	144
26	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. <i>BMC Cancer</i> , 2007, 7, 73.	1.1	134
27	CD44 regulates epigenetic plasticity by mediating iron endocytosis. <i>Nature Chemistry</i> , 2020, 12, 929-938.	6.6	132
28	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. <i>Nature Medicine</i> , 2017, 23, 568-578.	15.2	131
29	<i>ZNF703</i> gene amplification at 8p12 specifies luminal B breast cancer. <i>EMBO Molecular Medicine</i> , 2011, 3, 153-166.	3.3	126
30	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low <i>Xist</i> Expression. <i>Clinical Cancer Research</i> , 2013, 19, 6520-6531.	3.2	122
31	Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers. <i>Clinical Cancer Research</i> , 2006, 12, 4533-4544.	3.2	121
32	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. <i>BMC Cancer</i> , 2006, 6, 245.	1.1	120
33	Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target. <i>Stem Cells</i> , 2012, 30, 1327-1337.	1.4	120
34	Identification and validation of an ERBB2 gene expression signature in breast cancers. <i>Oncogene</i> , 2004, 23, 2564-2575.	2.6	117
35	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. <i>Cell Reports</i> , 2017, 18, 2256-2268.	2.9	111
36	Breast cancer stem cells: tools and models to rely on. <i>BMC Cancer</i> , 2009, 9, 202.	1.1	105

#	ARTICLE	IF	CITATIONS
37	ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. <i>Cancer Research</i> , 2013, 73, 7290-7300.	0.4	103
38	TACC1- $\alpha$ -TUBULIN-Aurora A protein complex in breast cancer. <i>Oncogene</i> , 2003, 22, 8102-8116.	2.6	99
39	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. <i>Oncogene</i> , 2007, 26, 298-307.	2.6	81
40	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2017, 28, 769-776.	0.6	77
41	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. <i>Oncogene</i> , 2002, 21, 5619-5630.	2.6	73
42	Moesin expression is a marker of basal breast carcinomas. <i>International Journal of Cancer</i> , 2007, 121, 1779-1785.	2.3	70
43	Mammary stem cell number as a determinate of breast cancer risk. <i>Breast Cancer Research</i> , 2007, 9, 109.	2.2	63
44	ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. <i>Oncogene</i> , 2007, 26, 7163-7169.	2.6	62
45	Comparative multi-methodological measurement of ERBB2 status in breast cancer. <i>Journal of Pathology</i> , 2004, 202, 286-298.	2.1	61
46	MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem-like Cells and Breast Tumor Development. <i>Cancer Research</i> , 2014, 74, 6648-6660.	0.4	59
47	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NGR1 gene. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 333-345.	1.5	56
48	Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. <i>Oncotarget</i> , 2015, 6, 3709-3721.	0.8	49
49	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. <i>PLoS ONE</i> , 2014, 9, e104302.	1.1	43
50	Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. <i>Breast Cancer Research</i> , 2014, 16, R52.	2.2	43
51	An iron hand over cancer stem cells. <i>Autophagy</i> , 2017, 13, 1465-1466.	4.3	43
52	Growth Hormone Is Secreted by Normal Breast Epithelium upon Progesterone Stimulation and Increases Proliferation of Stem/Progenitor Cells. <i>Stem Cell Reports</i> , 2014, 2, 780-793.	2.3	42
53	Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. <i>Oncotarget</i> , 2016, 7, 56558-56573.	0.8	34
54	Brief Reports: A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome. <i>Stem Cells</i> , 2014, 32, 3031-3036.	1.4	33

#	ARTICLE	IF	CITATIONS
55	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. <i>Cancer Research</i> , 2015, 75, 3373-3383.	0.4	32
56	CD95/Fas and metastatic disease: What does not kill you makes you stronger. <i>Seminars in Cancer Biology</i> , 2020, 60, 121-131.	4.3	31
57	Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 204-218.	1.5	30
58	ETV6 gene rearrangements in invasive breast carcinoma. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 103-108.	1.5	30
59	A genome-wide <i>scRNA</i> screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e9930.	3.3	27
60	Getting to the Root of BRCA1-Deficient Breast Cancer. <i>Cell Stem Cell</i> , 2009, 5, 229-230.	5.2	23
61	PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. <i>Nature Chemical Biology</i> , 2019, 15, 358-366.	3.9	22
62	XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation. <i>Cell</i> , 2022, 185, 2164-2183.e25.	13.5	22
63	p53 and cancer stem cells: The mevalonate connexion. <i>Cell Cycle</i> , 2012, 11, 2583-2584.	1.3	21
64	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. <i>International Journal of Cancer</i> , 2003, 107, 854-862.	2.3	19
65	Basal and luminal breast cancers: Basic or luminous? (Review). <i>International Journal of Oncology</i> , 2004, 25, 249.	1.4	18
66	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/ $\beta$ -Catenin Signaling. <i>Stem Cell Reports</i> , 2018, 11, 1040-1050.	2.3	18
67	How to best classify breast cancer: Conventional and novel classifications (Review). <i>International Journal of Oncology</i> , 2005, 27, 1307.	1.4	17
68	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018, 9, 33762-33777.	0.8	17
69	CD95/Fas suppresses NF- $\kappa$ B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. <i>iScience</i> , 2021, 24, 103538.	1.9	16
70	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. <i>Breast</i> , 2007, 16, 352-358.	0.9	15
71	A stem cell population at the anorectal junction maintains homeostasis and participates in tissue regeneration. <i>Nature Communications</i> , 2021, 12, 2761.	5.8	15
72	HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings. <i>PLoS ONE</i> , 2017, 12, e0185400.	1.1	13

#	ARTICLE	IF	CITATIONS
73	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. <i>Cell Death and Disease</i> , 2022, 13, 96.	2.7	13
74	Targeting breast cancer stem cells: fishing season open!. <i>Breast Cancer Research</i> , 2010, 12, 312.	2.2	11
75	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016, 7, 79428-79441.	0.8	11
76	miRViz: a novel webserver application to visualize and interpret microRNA datasets. <i>Nucleic Acids Research</i> , 2020, 48, W252-W261.	6.5	10
77	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. <i>IScience</i> , 2021, 24, 103348.	1.9	10
78	How to best classify breast cancer: conventional and novel classifications (review). <i>International Journal of Oncology</i> , 2005, 27, 1307-13.	1.4	9
79	Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells. <i>International Journal of Oncology</i> , 2002, 21, 989.	1.4	7
80	Breast tumor microenvironment: In the eye of the cytokine storm. <i>Cell Cycle</i> , 2011, 10, 2421-2421.	1.3	7
81	Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. <i>Proteomics</i> , 2019, 19, e1800454.	1.3	7
82	Breast cancer stem cells programs: enter the (non)-code. <i>Briefings in Functional Genomics</i> , 2016, 15, 186-199.	1.3	6
83	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	1.0	5
84	Cancer stem cells: Just sign here!. <i>Cell Cycle</i> , 2010, 9, 227-232.	1.3	3
85	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. <i>Journal of Pathology</i> , 2012, 227, 267-269.	2.1	2
86	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. <i>Cancers</i> , 2022, 14, 2404.	1.7	2
87	S17 Breast cancer stem cells: Getting to treat the core. <i>Breast</i> , 2009, 18, S7-S8.	0.9	1
88	Correction: Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks: Figure 4.. <i>Cancer Research</i> , 2011, 71, 2407-2407.	0.4	1
89	Loss of <i>XIST</i> Impairs Human Mammary Stem Cell Differentiation and Increases Tumorigenicity Through Enhancer and Mediator Complex Hyperactivation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
90	P1-04-07: Poly (ADP-Ribose) Polymerase-1 (PARP-1) Is Overexpressed in Human Breast Cancer Stem Cells: Results from a Proteomic-Based Approach.. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
91	Abstract 10: Characterization of ovarian CSC using ALDH and CD133 identifies a cancer stem cell hierarchy. , 2010, , .		1
92	Abstract 13: Regulation of breast cancer stem cells by miR-93. , 2010, , .		1
93	Abstract 3881: A distinct DNA methylation signature defines breast cancer stem cells and predict cancer outcome. , 2014, , .		1
94	Flick the cancer stem cells' switch to turn cancer off. Molecular and Cellular Oncology, 2017, 4, e1319896.	0.3	0
95	Abstract 3322: Protective antitumor immunity induced by ALDEFLUOR+ enriched cancer stem cells. , 2010, , .		0
96	Abstract 749: Cancer stem cell vaccination confers significant anti-tumor immunity by selectively targeting cancer stem cells. , 2011, , .		0
97	Abstract A57: Targeting breast cancer stem cells by inducing cell differentiation using histone deacetylase inhibitor S78454.. , 2011, , .		0
98	Abstract B11: A panel of patient-derived xenografts for preclinical efficacy studies in various breast cancer molecular subtypes.. , 2011, , .		0
99	Abstract 3327: Role of microRNA221 in breast cancer stem cell expansion and induction of EMT. , 2012, , .		0
100	Abstract LB-190: Growth hormone signaling in mammary stem and progenitor cells. , 2012, , .		0
101	Abstract 3310: microRNAs regulate the transition between EMT and MET breast cancer stem cell states. , 2012, , .		0
102	Abstract 5339: Breast cancer stem cells predict engraftment in vivo of primary tumor and are characterized by a gene expression signature associated with poor prognosis.. , 2012, , .		0
103	Abstract B082: Role of CD44v6 in acquired resistance to anti-angiogenic therapy of triple-negative breast cancer. , 2013, , .		0
104	Abstract C115: Response to trastuzumab of HER2-overexpressing breast cancer patient-derived xenografts depends on the host mouse strain.. , 2013, , .		0
105	Abstract 3020: Patient-derived xenograft (PDX) models to study the role of breast cancer stem cells in metastasis formation. , 2014, , .		0
106	Abstract P4-13-23: Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH) and patient-derived tumor xenograft (PDX) for precision medicine in advanced breast cancer: A single-center prospective study. , 2016, , .		0
107	Abstract 4790: Breast cancer stem cells: The next step in the area of personalized medicine. , 2016, , .		0
108	Abstract P2-10-02: AVASTEM “ Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for locally advanced breast cancers: A prospective proof of concept randomized phase II trial. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
109	Genome-wide RNA interference screen in cancer stem cells. <i>Methods in Cell Biology</i> , 2022, , .	0.5	0